NEW YORK (GenomeWeb News) - Invitrogen has licensed cell proliferation assay technology from Harvard University that it will use in its click chemistry technology-related programs, the company said today.

The company said it is adding the Harvard technology to its click chemistry IP portfolio, which includes a license from the Scripps Research Institute and agreements with the University of California, Berkeley, the California Institute of Technology, and the National Institutes of Health.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.